2-〔β-pyridyl-（2"）-ethenyl〕-3-（2'-methylphenyl）-quinazolingne-（4）（B169）のてんかんに対する使用経験

CLINICAL EVALUATION OF 2-〔β-PYRIDYL-(2")-ETHENYL〕-3-(2'-METHYLPHENYL)-QUINAZOLINONE-(4) (B169) IN THE TREATMENT OF EPILEPTICS IN INFANCY AND CHILDHOOD

緒言

　抗けいれん剤のめざましい最近の進歩によつて，難治性てんかんが減少してきたとはいえ，なお残されている各種発作型患者に対して，更に新しい薬剤の出現が待たれている。

　2-〔β-pyridyl-（2"）-ethenyl〕-3-（2'-methylphenyl）-quinazolinone-（4）（以下B169と略称する）は，1963年Boltzeら^1）により合成されたquinazolinone誘導体であり，その構造式は次のようである。従来の抗けいれん剤とはことなつた特異な化学構造を有する物質である。本剤の抗けいれん作用，生体内代謝に関する動物実験は，Boltzeら^1），森ら^2）によつて行なわれ，その有効性が報告されている。

Thirty epileptics with the age varying from 3 months to 13 years who had grand mal (9 cases), focal motor seizures (3 cases), psychomotor seizures (3 cases), autonomic seizures (2 cases), petit mal absence (1 case), myoclonic jerks (2 cases), infantile spasms (4 cases), grand mal and focal motor seizures (3 cases) and other mixed seizures (3 cases) were treated with 2-〔β-pyridyl-(2")-etheny1〕-3-(2'-methylphenyl) -quinazolinone-(4) (B169) for periods from one week to 14 months.

In our series, nine fresh cases without history of previous therapy were treated by this drug only and other 21 cases were intractable to conventional anticonvulsant drugs, to which B-169 was newly added.

The results were as follows.

1) This drug was effective in the treatment of focal motor seizures and of some value in psycho-motor seizures and autonomic seizures, but less ef-fective against grand mal and of little value in petit mal absence, myoclonic jerks and infantile spasms.

2) Relatively favorable electroencephalographic finding in regard to the effectiveness of this drug appeared to be focal spike and unfavorable electro-encephalographic finding was generalized multiple or single spike & wave complex.

3) No toxic effects on liver function (GOT, GPT, alkali-phosphatase, TTT and ZnTT), peripheral blood and urine analysis could be demonstrated. Transient side effects (drowsiness and ataxia) were noted in 5 cases, but these were slight and tempo-rary one.